| Literature DB >> 26705758 |
Remi A Kessler1, Maureen A Mealy1, Michael Levy2.
Abstract
OPINION STATEMENT: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.Entities:
Keywords: Azathioprine; Eculizumab; Immunosuppression; Mycophenolate; Neuromyelitis optica spectrum disorder; Rituximab
Year: 2016 PMID: 26705758 PMCID: PMC4807395 DOI: 10.1007/s11940-015-0387-9
Source DB: PubMed Journal: Curr Treat Options Neurol ISSN: 1092-8480 Impact factor: 3.598